CORONA, Calif. (AP) — Watson Pharmaceuticals said Wednesday federal regulators are inspecting a manufacturing site that has been under government scrutiny for several years.

 

The Davie, Fla., facility has been subject to a new product hold by the Food and Drug Administration since 2005. FDA indicated it will not approve any new drugs that would be manufactured at the site until manufacturing problems there are fixed.

 

Watson acquired the site in 2006 as part of its buyout of Andrx Corp.

 

Shares of Watson Pharmaceuticals Inc. rose 51 cents Wednesday to close at $26.79.